skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
BRAF(V600E) Inhibitor CEP-32496 (Code C107245)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: BRAF(V600E) Inhibitor CEP-32496

Definition: An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. CEP-32496 specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.

Display Name: BRAF(V600E) Inhibitor CEP-32496

Label: BRAF(V600E) Inhibitor CEP-32496

NCI Thesaurus Code: C107245 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3502778  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride
BRAF(V600E) Inhibitor CEP-32496

External Source Codes: 
PDQ Closed Trial Search ID 750855
PDQ Open Trial Search ID 750855 (check for NCI PDQ open clinical trial info)
UMLS CUI C3502778

Other Properties:
     Name Value (qualifiers indented underneath)
code C107245
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom